Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$7.64 +7.9%	$6.78	$5.81 ▼ $14.38	$631.67M	0.83	399,140 shs	603,873 shs
LMAT LeMaitre Vascular	$100.33 +4.0%	$85.60	$71.42 ▼ $109.58	$2.27B	0.79	190,309 shs	180,550 shs
LQDA Liquidia Technologies	$26.84 -1.7%	$17.26	$8.75 ▼ $28.00	$2.31B	0.14	1.79 million shs	2.60 million shs
PRCT PROCEPT BioRobotics	$41.23 +4.8%	$52.98	$37.12 ▼ $103.81	$2.29B	1.05	1.02 million shs	727,270 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	-1.80%	-3.54%	+9.94%	+8.42%	-22.37%
LMAT LeMaitre Vascular	-0.27%	+0.67%	+19.98%	+18.49%	+11.49%
LQDA Liquidia Technologies	-0.18%	+4.64%	+64.46%	+77.85%	+173.55%
PRCT PROCEPT BioRobotics	-0.08%	-1.92%	-33.03%	-31.42%	-52.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVS Bioventus	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	2.233 of 5 stars	1.2	2.0	3.3	0.0	3.0	2.5	1.3
LQDA Liquidia Technologies	3.4999 of 5 stars	3.5	3.0	0.0	0.0	2.9	4.2	0.6
PRCT PROCEPT BioRobotics	3.5454 of 5 stars	4.4	1.0	0.0	0.0	4.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.75	Moderate Buy	$13.75	79.97% Upside
LMAT LeMaitre Vascular	2.40	Hold	$97.60	-2.72% Downside
LQDA Liquidia Technologies	3.00	Buy	$32.11	19.64% Upside
PRCT PROCEPT BioRobotics	2.78	Moderate Buy	$74.88	81.60% Upside

Current Analyst Ratings Breakdown

Latest BVS, PRCT, LQDA, and LMAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	LQDA Liquidia Technologies	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$43.00
8/13/2025	LQDA Liquidia Technologies	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$33.00 ➝ $41.00
8/13/2025	LQDA Liquidia Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $31.00
8/12/2025	LQDA Liquidia Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/7/2025	PRCT PROCEPT BioRobotics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $58.00
8/7/2025	PRCT PROCEPT BioRobotics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$80.00 ➝ $55.00
8/6/2025	LMAT LeMaitre Vascular	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$92.00 ➝ $95.00
8/6/2025	LMAT LeMaitre Vascular	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$95.00
7/22/2025	LMAT LeMaitre Vascular	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
7/15/2025	PRCT PROCEPT BioRobotics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$71.00 ➝ $68.00
7/9/2025	PRCT PROCEPT BioRobotics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$564.14M	1.12	$0.61 per share	12.58	$2.80 per share	2.73
LMAT LeMaitre Vascular	$219.86M	10.33	$2.48 per share	40.49	$16.02 per share	6.26
LQDA Liquidia Technologies	$19.32M	119.59	N/A	N/A	$0.18 per share	149.11
PRCT PROCEPT BioRobotics	$224.50M	10.22	N/A	N/A	$6.93 per share	5.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	-$156.23M	N/A	N/A	16.61	N/A	-7.11%	15.61%	4.01%	N/A
LMAT LeMaitre Vascular	$44.04M	$2.06	48.70	46.24	2.49	20.08%	13.67%	9.14%	10/30/2025 (Estimated)
LQDA Liquidia Technologies	-$130.39M	-$1.70	N/A	N/A	N/A	-732.17%	-232.96%	-60.81%	N/A
PRCT PROCEPT BioRobotics	-$91.41M	-$1.55	N/A	N/A	N/A	-30.60%	-23.73%	-17.34%	10/27/2025 (Estimated)

Latest BVS, PRCT, LQDA, and LMAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	LQDA Liquidia Technologies	-$0.43	-$0.49	-$0.06	-$0.49	$3.90 million	$8.84 million
8/6/2025	Q2 2025	PRCT PROCEPT BioRobotics	-$0.41	-$0.35	+$0.06	-$0.35	$75.67 million	$79.18 million
8/5/2025	Q2 2025	LMAT LeMaitre Vascular	$0.57	$0.60	+$0.03	$0.60	$62.48 million	$63.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.80%	N/A	38.83%	14 Years
LQDA Liquidia Technologies	N/A	N/A	N/A	N/A	N/A
PRCT PROCEPT BioRobotics	N/A	N/A	N/A	N/A	N/A

Latest BVS, PRCT, LQDA, and LMAT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	LMAT LeMaitre Vascular	quarterly	$0.20	0.9%	8/21/2025	8/21/2025	9/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	1.85	1.41	0.99
LMAT LeMaitre Vascular	0.46	13.96	11.74
LQDA Liquidia Technologies	9.84	2.49	2.41
PRCT PROCEPT BioRobotics	0.13	9.21	7.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
LMAT LeMaitre Vascular	84.64%
LQDA Liquidia Technologies	64.54%
PRCT PROCEPT BioRobotics	89.46%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	33.00%
LMAT LeMaitre Vascular	9.50%
LQDA Liquidia Technologies	26.50%
PRCT PROCEPT BioRobotics	6.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	1,200	82.68 million	54.46 million	Not Optionable
LMAT LeMaitre Vascular	490	22.64 million	20.49 million	Optionable
LQDA Liquidia Technologies	50	86.09 million	63.28 million	Optionable
PRCT PROCEPT BioRobotics	430	55.64 million	51.96 million	Optionable

BVS, PRCT, LQDA, and LMAT Headlines

Recent News About These Companies

Osterweis Capital Management Inc. Has $10.12 Million Stake in PROCEPT BioRobotics Corporation $PRCT

August 22 at 7:13 AM | marketbeat.com

PROCEPT BioRobotics (PRCT) Outlook Adjusted as System Replacement Forecasts Shift

August 22 at 3:24 AM | uk.finance.yahoo.com

Analyzing PROCEPT BioRobotics (NASDAQ:PRCT) and Thermo Fisher Scientific (NYSE:TMO)

August 22 at 3:23 AM | americanbankingnews.com

Kovitz Investment Group Partners LLC Makes New $2.15 Million Investment in PROCEPT BioRobotics Corporation $PRCT

August 21 at 4:07 AM | marketbeat.com

PROCEPT BioRobotics Corporation $PRCT Holdings Trimmed by Vanguard Group Inc.

August 19 at 3:46 AM | marketbeat.com

Sit Investment Associates Inc. Raises Stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

August 18, 2025 | marketbeat.com

Deutsche Bank AG Cuts Stock Position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

August 18, 2025 | marketbeat.com

Sei Investments Co. Sells 8,550 Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

August 17, 2025 | marketbeat.com

Lord Abbett & CO. LLC Decreases Holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

August 17, 2025 | marketbeat.com

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 17, 2025 | marketbeat.com

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Average Recommendation of "Moderate Buy" from Analysts

August 16, 2025 | americanbankingnews.com

Entropy Technologies LP Acquires Shares of 7,100 PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

August 15, 2025 | marketbeat.com

Procept BioRobotics director buys 785K in common stock

August 15, 2025 | msn.com

Procept BioRobotics: Increasing Average Selling Price, Initiate At Buy

August 14, 2025 | seekingalpha.com

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd.

August 14, 2025 | marketbeat.com

Leerink Partners Reiterates a Buy Rating on PROCEPT BioRobotics (PRCT)

August 13, 2025 | msn.com

Leerink Partnrs Issues Pessimistic Outlook for PRCT Earnings

August 12, 2025 | americanbankingnews.com

William Blair Issues Pessimistic Outlook for PRCT Earnings

August 12, 2025 | americanbankingnews.com

PROCEPT BioRobotics (NASDAQ:PRCT) Stock Rating Upgraded by Wall Street Zen

August 11, 2025 | americanbankingnews.com

Leerink Partnrs Has Negative Forecast for PRCT Q3 Earnings

August 11, 2025 | marketbeat.com

William Blair Issues Negative Forecast for PRCT Earnings

August 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS, PRCT, LQDA, and LMAT Company Descriptions

Bioventus NYSE:BVS

$7.64 +0.56 (+7.91%)

Closing price 04:00 PM Eastern

Extended Trading

$7.64 0.00 (-0.07%)

As of 04:10 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

LeMaitre Vascular NASDAQ:LMAT

$100.33 +3.88 (+4.02%)

Closing price 04:00 PM Eastern

Extended Trading

$99.86 -0.47 (-0.46%)

As of 05:12 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Liquidia Technologies NASDAQ:LQDA

$26.84 -0.46 (-1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$26.92 +0.09 (+0.32%)

As of 06:49 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

PROCEPT BioRobotics NASDAQ:PRCT

$41.23 +1.88 (+4.78%)

Closing price 04:00 PM Eastern

Extended Trading

$41.29 +0.06 (+0.15%)

As of 06:53 PM Eastern

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time